Weiss KE, et al. - This trial investigated the efficacy of transarterial chemoembolization (TACE) in patients aged 4-17 years (4 male, mean 12.5 years) who underwent TACE for unresectable hepatocellular carcinoma (HCC). Response to TACE was evaluated by change in AFP, RECIST and tumor volume, PRETEXT, and transplantation eligibility by UCSF and Milan criteria. Findings disclosed that following transplantation, 5 patients were alive at the end of the follow-up period and 1 died of recurrent disease. It was also deduced that TACE for children with unresectable HCC served as a safe and effective method for managing hepatic tumor burden and for downstaging and bridging to liver transplantation.